The global medical industry experienced a 65% drop in company filings mentions of COVID-19 in Q2 2023 compared with the previous quarter, with the highest share accounted for by Abbott Laboratories with 29% year-on-year decrease, according to GlobalData’s analysis of over 466 medical company filings.

Notably, COVID-19 was one of the most frequently referenced themes in Q2 2023, ranking highest in terms of mentions, ahead of industrial automation and robotics, according to GlobalData.

Of the top leading companies in the medical industry, Abbott Laboratories had the greatest increase in references for COVID-19 in Q2 2023, compared with the previous quarter. GlobalData identified 61 COVID-19-related sentences in the company's filings - 2% of all sentences - and a decrease of 29% in Q2 2023 compared with Q2 2022. Danaher’s mentions of COVID-19 dropped by 19% to 57 and Hologic’s by 25% to 51 and Laboratory Corp of America Holdings’s by 150% to 50 and Sartorius’s by 360% to 46.

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for COVID-19 in Q2 2023 was 115.

This content was updated on 5 August 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.